These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15726597)

  • 21. Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor.
    Cholongitas E; Pipili C; Katsogridakis K; Relos K; Dasenaki M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1083-4. PubMed ID: 17680243
    [No Abstract]   [Full Text] [Related]  

  • 22. Managing cutaneous reactions to imatinib therapy.
    Rule SA; O'Brien SG; Crossman LC
    Blood; 2002 Nov; 100(9):3434-5. PubMed ID: 12412577
    [No Abstract]   [Full Text] [Related]  

  • 23. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
    Brazzelli V; Prestinari F; Roveda E; Barbagallo T; Bellani E; Vassallo C; Orlandi E; Passamonti F; Borroni G
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S240-3. PubMed ID: 16227099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
    Simpson E; O'Brien SG; Reilly JT
    Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 28. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
    Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
    Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 30. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases.
    Pascual JC; Matarredona J; Miralles J; Conesa V; Borras-Blasco J
    Int J Dermatol; 2006 Dec; 45(12):1471-3. PubMed ID: 17184272
    [No Abstract]   [Full Text] [Related]  

  • 32. [Lichenoid cutaneous reaction to imatinib].
    Roux C; Boisseau-Garsaud AM; Saint-Cyr I; Hélénon R; Quist D; Delaunay C
    Ann Dermatol Venereol; 2004; 131(6-7 Pt 1):571-3. PubMed ID: 15318140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keratoacanthomas associated with imatinib mesylate.
    Balagula Y; Busam KJ; Carvajal RD; Wolchok JD; Myskowski PL
    Acta Oncol; 2011 May; 50(4):593-5. PubMed ID: 21108567
    [No Abstract]   [Full Text] [Related]  

  • 34. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).
    Esmaeli B; Diba R; Ahmadi MA; Saadati HG; Faustina MM; Shepler TR; Talpaz M; Fraunfelder R; Rios MB; Kantarjian H
    Eye (Lond); 2004 Jul; 18(7):760-2. PubMed ID: 14739914
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Takeuchi M; Koseki M; Uryu H
    Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
    [No Abstract]   [Full Text] [Related]  

  • 36. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 37. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 38. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib-induced erythroderma.
    Mathew T; Chandrashekar L; Pulimood S; Srivastava A
    Australas J Dermatol; 2007 Aug; 48(3):193-4. PubMed ID: 17680975
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cutaneous side effects with imatinib (Glivec)].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2004 May; 131(5):517-8. PubMed ID: 15235550
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.